Biocat and Leitat will coordinate two of the five RIS3CAT Communities Blog Post

The RIS3CAT Community for Digital applications in biotechnology and health therapies –coordinated by Biocat from its headquarters at the Barcelona Science Park (PCB)– is one of the first RIS3CAT Communities to which Government of Catalonia, through ACCIÓ, has allocated 19.1 million Euros from the ERDF fund (European Regional Development Fund). Leitat –whose BioMed Division is based at PCB– will also coordinate a further RIS3CAT Community for New diagnostic devices and big data applied to health, in which Intelligent Pharma, located at PCB, leads one of the four projects: ‘Diabetes as an accelerator of cognitive derioration in Alzheimer´s disease: Integral approach and treatment adherence’.

 

Discovery of molecular protection linked to a degenerative neuromuscular disease Blog Post

Xavier Salvatella, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) at PCB, in collaboration with scientists from the University of Florence (Italy), has described a molecular system of protection that involves the androgen receptor protein, a molecule that is mutated in patients with Kennedy’s disease and which cause progressive muscle wastage.

 

The call to take part in the 15th Edition of Spend the Summer at the Park! is now open Blog Post

Starting today, June 6, applications are being accepted to take part in the internship program Spend the Summer at the Park!, aimed at students doing theirs master´s degree or in their final year of their bachelor’s degree. The aim of this initiative, organized by the Parc Cientific de Barcelona (PCB), is to bring research closer to young students from any university in the world through their participation in projects undertaken at PCB. The deadline for submitting applications is June 20.

 

The Barcelona Science Park starts BATX2LAB Blog Post

The Barcelona Science Park (PCB) just opened the call to participate at the 12th edition of BATX2LAB, a tutoring program for secondary school students who undertake research projects. The initiative is part of the Research in Society program -organized by PCB´s Science Outreach Division- that offers around 80 activities addressed at different audiences from a wide age range with a participation of over 4,5000 people each year.

 

EIT Health launches two funding calls for innovative health projects Blog Post

EIT Health has lunched two funding initiatives: the grants Headstart and Proof of Concept and the Business Plan Aggregator program. As part of the EIT Health accelerator, both ideas are geared to innovative business ideas, SMEs, spin-offs and start-up committed to the social challenges defined by EIT´s principles: promoting a healthy lifestyle, supporting active ageing and improving quality of life through better healthcare. EIT Health Spain is based at the Barcelona Science Park (PCB) and at presently brings together 18 leading public and private organizations in the three areas of the innovation triangle: research, education and business creation.

 

New evidence on molecular mechanisms involved in psoriasis outset Blog Post

Two translational research studies published in the high impact scientific magazines Journal of Allergy and Clinical Immunology and Journal of Investigative Dermatology have described new immunologic mechanisms in psoriasis, a chronic cutaneous inflammatory disease which affects around the 2% of the population. The studies have been led by Lluís Francesc Santamaria, Director of the group of Translationary Immunology of the University of Barcelona (UB) based at the Barcelona Science Park, together with researchers of the Hospital del Mar and the Municipal Institute for Medical Research, among others.

 

The turnonver of the 734 companies of the BioRegion amounts to 7% of Catalonia´s GDP Blog Post

The life sciences and healthcare sector of Catalonia gathers 734 companies with a turnover of 14.360 million euros, 7% of Catalonia’s GDP and employs 42,133 workers. These are some of the data yielded by the 2015 Biocat Report, presented last Thursday at the Palau de la Generalitat, which brought more than 200 politicians, business people and figures from academia and science. The event was presided over by the President of the Government of Catalonia, Carles Puigdemont, with the participation of Albert Barberà, CEO at Biocat, the organization that coordinates and promotes the health and life sciences sector in Catalonia, and Ella Korets-Smith, executive director of TO Health!, the Toronto´s life science cluster. 

 

IDP Pharma closes a funding round for 2 million euros Blog Post

IDP Pharma, founded in 2015 and with headquarters at the Barcelona Science Park (PCB) has raised, during its first operative year, over 2 million euros from public and private capital. The biopharmaceutical company –specializes in the development of drugs for cancer treatment directed to a new class of therapeutic targets: IDPs– will appoint this capital to continue the preclinical development of their most advanced products: two first-in-class molecules with antitumor activity for Multiple Myeloma, the second most common blood cancer

 

Mundipharma-Purdue reach a new deal to in-licence from Esteve full global rights for novel first-in-class AS1 for the management of pain Blog Post

Mundipharma its independent associated company Purdue Pharma today announced that, following completion of Phase II studies, they have exercised their option and taken over full responsibility from Laboratorios Esteve for the clinical, regulatory and commercial development of a potential first-in-class sigma-1 antagonist (AS1 o MR309/E-52862). In June 2012, Esteve has moved its Center for Drug Discovery and Preclinical Development to the Barcelona Science Park (PCB) in an attempt to shorten development time and speed up the arrival to market of innovative new drugs.